|
Press Releases |
|
|
|
Friday, March 29, 2019 |
|
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease |
Eisai Co., Ltd. announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies (MISSION AD) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in early Alzheimer's disease (AD). more info >> |
|
Friday, March 22, 2019 |
|
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease |
Eisai Co., Ltd. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc. more info >> |
|
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases |
Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline, including anti-amyloid beta (Abeta) protofibril antibody BAN2401 and oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat will be given at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD). more info >> |
|
Thursday, March 21, 2019 |
|
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease |
Biogen and Eisai, Co., Ltd. announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia. more info >> |
|
Tuesday, March 12, 2019 |
|
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia |
Eisai Co., Ltd. and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, L.P. have announced that the U.S. FDA has accepted for review the NDA for lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder. more info >> |
|
Thursday, March 7, 2019 |
|
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan |
Eisai Co., Ltd. announced today that a marketing authorization application has been submitted in Japan for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for use in the treatment of insomnia disorder. more info >> |
|
Wednesday, February 27, 2019 |
|
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan |
Eisai Co., Ltd. has entered an agreement to support the international non-governmental organization Association for Aid and Relief, Japan's program to raise awareness of mycetoma in Sudan. more info >> |
|
Thursday, February 21, 2019 |
|
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa |
AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they have received approval for an additional indication of HUMIRA (generic name: adalimumab [recombinant]), a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa (HS). more info >> |
|
Wednesday, February 13, 2019 |
|
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy |
Eisai Co., Ltd. announced today that it has submitted an application to the European Medicines Agency (EMA) for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval for use in pediatric patients with epilepsy. more info >> |
|
Monday, February 4, 2019 |
|
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study |
Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Vietnam: International Dairy Product launches nutritious KUN milk with jelly pieces in SIG XSlimBloc carton packs
May 20, 2024 19:30 HKT/SGT
|
|
|
InsureTech Connect Asia: Asia's Largest Insurance Ecosystem Conference
May 20, 2024 18:08 HKT/SGT
|
|
|
BEAST (Bengkel Animasi Digital Arts & Creative Festival) 2024 goes back to Bandung
May 20, 2024 18:00 HKT/SGT
|
|
|
Paw Pro GmbH Announces $1.5M Partnership with Health Reasoning to Launch Innovative Web3 Platform
May 20, 2024 17:03 HKT/SGT
|
|
|
Response to Africa Intelligence Article
May 20, 2024 17:00 HKT/SGT
|
|
|
Shaping a Green Future for Textile Industry- Aimer 2024 New Presentation of Seaweed Fiber Pajamas
May 20, 2024 17:00 HKT/SGT
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 20, 2024 16:00 HKT/SGT
|
|
|
The cybersecurity capital of Philippines, PhilSec now an essential choice for critical infrastructure
May 20, 2024 15:43 HKT/SGT
|
|
|
MHI Receives Order for Additional 12 Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France
May 20, 2024 11:36 JST
|
|
|
REDEX to be an exclusive partner to TNBX in Malaysia to support the Malaysia Green Attribute Trading System (mGATS) platform
May 20, 2024 10:00 HKT/SGT
|
|
|
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair conclude successfully
May 19, 2024 15:06 HKT/SGT
|
|
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation
May 17, 2024 22:29 HKT/SGT
|
|
|
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit
May 17, 2024 20:09 HKT/SGT
|
|
|
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards
May 17, 2024 16:37 HKT/SGT
|
|
|
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London
May 17, 2024 15:48 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|